NanoBio Gets Up To $10M From Feds To Develop Flu VaccineNanoBio Corp. will get an initial contract of $5.5 million and up to $5 million more to devleop its nanoemulsion technology to improve the performance of flu vaccines.
NanoBio Closes $11 Million Series C FinancingNanoBio Corp. announced Wednesday the closing of an $11 million Series C financing, including full participation from its existing investor syndicate.
NanoBio Publishes Study Results For Intranasal Nanoemulsion VaccineAnn Arbor-based NanoBio Corp. says newly published experimental data shows that its nanoemulsion-based flu vaccine has elicited robust immunity to the flu in animal tests on ferrets.
Event Notices From September 10-12
NanoBio Gets Patent On Cold Sore Product